Bionomics IPO Presentation Deck

BNC210 Phase 2 Social Anxiety Disorder Trial Social Anxiety Disorder Study Highlights ✓ Potential to conduct a cost-effective trial with an efficacy endpoint conducive to rapid data generation ✓ Ability to leverage development strategies of other Social Anxiety Disorder public CNS trial designs Received FDA clearance for IND filing and FDA Fast Track designation Phase 2 trial on target to start by end of 2021 and read out topline data by end of 2022 Bionomics Phase 2 Acute Social Anxiety Disorder PREVAIL Study Design Screening -50 225 mg BNC 210 60m LSAS = 70 Randomization (Double-blind) 50 -50 675 mg BNC 210 60min SINGLE ANXIETY CHALLENGE Årsase PLACEBO -50 FDA Fast Track designation 60mm PREVAIL Study 15 LIEBOWITZ SOCIAL ANXIETY SCALE >95: Very severe social phobia 80-95: Severe social phobia 65-80: Marked social phobia 55-65: Moderate social phobia ↓ EFFICACY ENDPOINT SUBIECTIVE UNITS OF DISTRESS SCALE (SUDS): Measures the self-reported intensity of anxiety and/or distress in SAD patients Topline data expected YE'22

View entire presentation